Financial Performance - As of June 30, 2024, Barinthus Bio reported cash, cash equivalents, and restricted cash of $117.8 million, down from $130.0 million as of March 31, 2024, with a net cash used in operating activities of $12.0 million in Q2 2024[8] - The net loss for Q2 2024 was $16.9 million, or $(0.43) per share, compared to a net loss of $15.5 million, or $(0.40) per share in Q1 2024[10] - The net loss attributable to Barinthus Biotherapeutics plc shareholders for the three months ended June 30, 2024, was $16,931,000, compared to a net loss of $23,802,000 for the same period in 2023, reflecting an improvement of 29.0%[14] - Total operating expenses for the three months ended June 30, 2024, were $18,863,000, down 29.5% from $26,671,000 in the same period of 2023[14] - General and administrative expenses rose to $7.2 million in Q2 2024 from $6.0 million in Q1 2024, largely due to foreign exchange losses[10] - Research and development expenses for the six months ended June 30, 2024, were $22,787,000, compared to $23,357,000 for the same period in 2023, a decrease of 2.4%[14] Research and Development - Research and development expenses increased to $11.7 million in Q2 2024 from $11.1 million in Q1 2024, primarily due to the progression of VTP-300 through ongoing Phase 2 trials[8] - The company has prioritized the development of VTP-300 for chronic hepatitis B and VTP-1000 for celiac disease following positive interim data[4] - The company plans to initiate the first human clinical trial of VTP-1000 for celiac disease in Q3 2024[5] - Interim data from the HBV003 trial indicated that nearly 20% of participants had undetectable HBsAg maintained for ≥16 weeks, and 76% were eligible for NUC discontinuation[3] - In the IM-PROVE II trial, 20% of participants in the VTP-300 treatment group had undetectable HBsAg at Week 72, compared to none in the placebo group[3] - Barinthus Bio expects to announce updated interim data from the HBV003 trial in Q4 2024[5] Assets and Liabilities - Total assets decreased from $214,506,000 on December 31, 2023, to $186,749,000 on June 30, 2024, representing a decline of approximately 12.9%[13] - Total current assets decreased from $156,905,000 to $131,879,000, a reduction of about 16.0%[13] - Total liabilities increased from $27,511,000 to $29,959,000, an increase of approximately 8.9%[13] - The accumulated deficit increased from $176,590,000 to $209,010,000, reflecting a rise of about 18.3%[13] - Cash and cash equivalents decreased from $142,090,000 to $117,774,000, a decline of about 17.1%[13] Shareholder Information - The weighted-average ordinary shares outstanding increased from 38,407,672 in June 30, 2023, to 39,041,111 in June 30, 2024, indicating a growth of approximately 1.6%[14] - The company reported no license revenue for the three months ended June 30, 2024, compared to $334,000 for the same period in 2023[14]

SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024. "We are thrilled to welcome Anne and Jennifer to our board as we prep ...

OXFORD, United Kingdom, June 12, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates, today announced plans to prioritize its pipeline to focus on the development of VTP-300 in CHB and VTP-1000 in celiac disease. The development of VTP-300 in CHB and VTP-1000 in celiac disease will be prioritized and the ongoing Phase 1 clinical trial of VTP-850 in prostate cancer will be completed. The Company ...

The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized. The pipeline prioritization is expected to result in a reduction in workforce of approximately 25% and an estimated extension to the cash runway into the second quarter of 2026. The decision follows the positive interim data from the two ongoing Phase 2 clinical trials presented at the European Association for the Study of the Liver (EASL) Congress on June 6, 2024. The data from the ongoing HBV003 and ...

Core Insights - Barinthus Biotherapeutics presented updated data from two clinical trials for chronic hepatitis B (CHB) at the EASL Congress 2024, highlighting the efficacy of VTP-300 in maintaining low HBsAg levels and the potential for NUC therapy discontinuation [4][6][9] Group 1: Trial Results - In the HBV003 trial, 67% of participants had HBsAg levels below 10 IU/mL, and 19% had undetectable HBsAg at the end of treatment or later, with 76% eligible for NUC therapy discontinuation [1][5] - The IM-PROVE II trial showed a statistically significant difference in HBsAg levels between the VTP-300 treatment group and placebo at 24 weeks post-treatment, with 84% of VTP-300 participants discontinuing standard NUC therapy compared to 53% in the placebo group [1][2][8] Group 2: Treatment Tolerability - Both VTP-300 and imdusiran were generally well-tolerated, with no serious adverse events reported, and the most common treatment-related adverse event was thyroid dysfunction in 9% of participants [5][6][8] - Robust T cell responses were observed, indicating a strong immune response to the treatment [5][6] Group 3: Future Directions - The company is eager to see further data from the ongoing trials, particularly regarding the combination of VTP-300 with nivolumab, which could advance towards a potential functional cure for hepatitis B [3][6] - An additional cohort in the IM-PROVE II trial is expected to provide preliminary data in the second half of 2024, focusing on the combination of imdusiran and VTP-300 with low doses of nivolumab [13]

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments "So far in 2024 we have continued to make strides across our programs. Notably, we received clearance from the FDA on an IND to progress VTP-1000 in a first in human clinical trial in celiac disease, as well as clearance from the Australian Ethics Committee on this trial. We expect to begin our Phase 1 trial of VTP-1000 in participants with celiac disease in the coming months. Additionally, we reported topline fi ...

OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, announced its financial results for the first quarter of 2024 and provided an overview of the Company's progress. "So far in 2024 we have continued to make strides across our programs. Notably, we received clear ...

OXFORD, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, today announced the appointment of Leon Hooftman, M.D., as Chief Medical Officer (CMO). "We are happy to welcome Dr. Hooftman to Barinthus Bio as our Chief Medical Officer. With his exper ...

Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events (AEs) or serious AEs (SAEs). Positive trends in clearance rate for both high-risk (hr)HPV (60%, Group 2) and cervical lesions (67%,Groups 2 and 5), were observed in the groups receiving the highest ChAdOx dose.Pooled data from the five different active dose groups demonstrated no statistically significant improvement in either hrHPV or cervical lesion clearance in comparison to the p ...

OXFORD, United Kingdom, March 20, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, announced its financial results for the year ended December 31, 2023, and an overview of the Company's progress. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. "2023 was a productive year for Barinthus Bio, with dat ...